Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis. by Kwok, CS et al.
Major bleeding after percutaneous
coronary intervention and risk
of subsequent mortality: a systematic
review and meta-analysis
Chun Shing Kwok,1 Sunil V Rao,2 Phyo K Myint,3 Bernard Keavney,1
James Nolan,4 Peter F Ludman,5 Mark A de Belder,6 Yoon K Loke,7
Mamas A Mamas1
To cite: Kwok CS, Rao SV,
Myint PK, et al. Major
bleeding after percutaneous
coronary intervention and
risk of subsequent mortality:
a systematic review and
meta-analysis. Open Heart
2014;1:e000021.
doi:10.1136/openhrt-2013-
000021
▸ Additional material is
published online only. To
view please visit the journal
online (http://dx.doi.org/10.
1136/openhrt-2013-000021).
Received 13 December 2013
Revised 11 January 2014
Accepted 18 January 2014
For numbered affiliations see
end of article.
Correspondence to
Dr Mamas A Mamas;
mamasmamas1@yahoo.co.uk
ABSTRACT
Objectives: To examine the relationship between
periprocedural bleeding complications and major
adverse cardiovascular events (MACEs) and mortality
outcomes following percutaneous coronary
intervention (PCI) and study differences in the
prognostic impact of different bleeding definitions.
Methods: We conducted a systematic review and
meta-analysis of PCI studies that evaluated
periprocedural bleeding complications and their impact
on MACEs and mortality outcomes. A systematic
search of MEDLINE and EMBASE was conducted to
identify relevant studies. Data from relevant studies
were extracted and random effects meta-analysis was
used to estimate the risk of adverse outcomes with
periprocedural bleeding. Statistical heterogeneity was
assessed by considering the I2 statistic.
Results: 42 relevant studies were identified including
533 333 patients. Meta-analysis demonstrated that
periprocedural major bleeding complications was
independently associated with increased risk of mortality
(OR 3.31 (2.86 to 3.82), I2=80%) and MACEs (OR 3.89
(3.26 to 4.64), I2=42%). A differential impact of major
bleeding as defined by different bleeding definitions on
mortality outcomes was observed, in which the
REPLACE-2 (OR 6.69, 95% CI 2.26 to 19.81), STEEPLE
(OR 6.59, 95% CI 3.89 to 11.16) and BARC (OR 5.40,
95% CI 1.74 to 16.74) had the worst prognostic impacts
while HORIZONS-AMI (OR 1.51, 95% CI 1.11 to 2.05)
had the least impact on mortality outcomes.
Conclusions: Major bleeding after PCI is independently
associated with a threefold increase in mortality and
MACEs outcomes. Different contemporary bleeding
definitions have differential impacts on mortality
outcomes, with 1.5–6.7-fold increases in mortality
observed depending on the definition of major bleeding
used.
INTRODUCTION
Advances in antithrombotic therapy have
improved the outcomes of patients undergoing
percutaneous coronary intervention (PCI)
through the reduction of ischaemic events at
the expense of increased procedure-related
bleeding complications. Major bleeding events
in contemporary PCI are signiﬁcant, with
30-day bleeding event rates reported between
0.7% and 1.1% in elective,1–3 0.6% and 4.7%3–6
in non-ST-elevation myocardial infarction
(NSTEMI) and 0.9% and 8.9% in ST-elevation
myocardial infarction (STEMI)3 4 7 8 depend-
ing on the deﬁnition used.
There are currently around 10 different
deﬁnitions of major bleeding used in trials
and registries of patients undergoing PCI9 10
and these deﬁnitions include various clinical
events, such as blood transfusion or retro-
peritoneal haemorrhage, laboratory para-
meters, such as differing values of
haemoglobin decreases, and clinical out-
comes such as mortality9 resulting in signiﬁ-
cant differences in bleeding event recording
across clinical trials thereby making compari-
sons between therapeutic strategies difﬁcult.
Furthermore, the incidence of major bleed-
ing varies depending on deﬁnition used. In
KEY MESSAGES
▸ The strength of this systematic review was the
large number of studies included with over half
a million total participants.
▸ Another strength was that we were able to evalu-
ate the effect of different major bleeding defini-
tions and its impact on risk of mortality and
major adverse cardiovascular events.
▸ This systematic review had the limitation that
studies included varied in antithrombotic and
antiplatelet regimes after PCI procedure.
▸ Another limitation was that the systematic review
was unable evaluate whether the subsequent
mortality was directly related to the bleed.
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one study, the RIVAL non-coronary artery bypass graft
(non-CABG) related major bleeding occurred in 0.87%
in the STEMI cohort and 0.57% in the NSTEMI group,
while if an ACUITY major bleeding deﬁnition was used,
major bleeding occurred in 3.1% in the STEMI group
and 2.26% in the NSTEMI group, respectively.
Major periprocedural bleeding complications follow-
ing PCI are predictors of mortality and major adverse
cardiovascular events (MACEs),11–13 with up to 12.1% of
all in-hospital mortality after PCI in the National
Cardiovascular Data Registry’s CathPCI Registry related
to bleeding complications.14 In contrast, other studies
have suggested that although bleeding may be causally
related to adverse outcomes in some patients in the real-
world setting, it is often merely a marker for patients at
higher risk for adverse outcomes.15 16
Some prior studies that have reported on the prognos-
tic impact of major bleeds have not accounted for differ-
ences in baseline covariates such as age, syndrome of
presentation and comorbidities that would themselves
impact on MACEs and mortality outcomes.17–21 In con-
trast, while other studies have adjusted for baseline cov-
ariates, different deﬁnitions of major bleeding such as
TIMI,2 11 22 23 GUSTO,20 24 STEEPLE20 25 and BARC23
have been used, which have been shown to have differ-
ential impacts on mortality/MACEs outcomes.20 23 26
Furthermore, the timing of bleeding from index PCI
procedures included in such studies has varied from
48 h,25 been limited to those that occur in hospital,23 27
to 30 days2 28 with impact on mortality and MACEs out-
comes studied at different time points such as 30
days,8 24 28 6 months24 27 or 1 year.2 22 23 25
Until today, there has not been a systematic review or
meta-analysis previously published studying the prognos-
tic impact of periprocedural major bleeding events on
mortality and MACEs outcomes following PCI. We have
therefore undertaken a meta-analysis to systematically
study the impact of major bleeding following PCI on
mortality and MACEs outcomes. In this meta-analysis, we
provide an overview of the cohorts evaluating the rates
of major bleeding events and systematically study the dif-
ferences in the prognostic impact of different bleeding
deﬁnitions and the relationship between major bleeding
and clinical events at different time points.
METHODS
Eligibility criteria
We selected studies of patients who underwent PCI that
reported on mortality or cardiovascular events among
patients with and without major bleeding events. There
was no restriction based on study design, deﬁnition of
major bleeding or the indication for PCI or its status as
an urgent or elective procedure. We excluded studies
that did not report on categories of major bleeding and
those that did not report either mortality or MACEs.
Search strategy
A search of EMBASE (1974 to January 2014) and
MEDLINE (1946 to January 2014) was conducted on
OvidSP. The search terms are shown in online supple-
mentary ﬁgure S1. We did not use any language restric-
tions. We checked the bibliographies of included studies
and relevant review articles found on the search for add-
itional relevant articles.
Study selection and data extraction
Two reviewers (CSK and YKL) checked all titles and
abstracts for studies that could potentially meet the
inclusion criteria. We retrieved full reports of these
potentially eligible studies and independently extracted
data on study design, participant characteristics, inter-
ventions used, major bleeding events, follow-up,
outcome events and methods of ascertaining measured
clinical events on to a preformatted spreadsheet. Any
discrepancies between the two reviewers were resolved
by consensus after consulting a third reviewer (MAM).
Quality assessment
Risk of bias was assessed by considering four different
areas: ascertainment of major bleeding events, ascertain-
ment of outcome events, extent of loss to follow-up and
the use of adjustment for confounders in the analysis.
We also assess for publication bias using funnel plots
when there were >10 studies available in the
meta-analysis and there was no evidence of substantial
statistical heterogeneity.29
Data analysis
We used RevMan V.5.1.7 (Nordic Cochrane Centre) to
do random effects meta-analysis using the inverse vari-
ance methods for pooled ORs. We assumed similarity
between the OR and other relative measures such as
relative risk, rate ratios or HRs because cardiovascular
events and death were rare events.30 The analysis was
stratiﬁed based on whether the results had considered
the effect of potential confounders through adjustments
or propensity-matched cohorts or not. In order to
reduce the risk of bias from confounding so that we
have a more reliable estimate of the independent effect
of bleeding on prognosis, we appraised studies with
multivariate adjustments or propensity-matched cohorts
separately from studies with crude or unadjusted results.
We used adjusted or propensity-matched risk estimates
where available. For datasets reporting multiple time
points, we took the earliest time point for the primary
analysis. Any later time points were subsequently ana-
lysed in the separate Forest plots stratiﬁed according to
timing of outcome assessment. Where there were mul-
tiple deﬁnitions of major bleeding we choose to use the
results for TIMI major bleeding.
We planned for three analyses. The primary analysis
was the pooled adjusted and unadjusted risk of mortality
with and without major bleed. The secondary analysis
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was the unadjusted and adjusted risk of MACEs with and
without major bleed. In a post hoc sensitivity analysis, we
conducted a pooled analysis after excluding studies
where it was clear that only some (and not all) of the
participants had undergone PCI.
Statistical heterogeneity
We used the I2 statistic to assess statistical heterogeneity.
I2 Values of 30–60% represent moderate levels of
heterogeneity.31
RESULTS
Study selection
The process of selection of studies is shown in online sup-
plementary ﬁgure S1. We retrieved 42 relevant studies of
patients that underwent PCI (total number of participants
533 333), which evaluated the risk of adverse events with
and without major bleeding.2 8 11 14 17–23 27 28 32–58 The
number of participants in each study ranged from 352 to
280 390 and the number of major bleeding events was
66 277 (37 studies, 15.3%). A total of 40 studies evaluated
mortality as an outcome and 11 studies reported on
MACEs.
Description of studies included
The study designs, date of study, country of origin and
indication for PCI is shown in table 1. There were 12
studies (149 650 participants), which were post hoc ana-
lyses of randomised controlled trials and 1 matched
observational study (280 390 participants). Of the
studies that reported number of centres, there were
more multicentre studies than single centre studies
(n=17 and n=13). The age and gender of participants
along with the antiplatelet and anticoagulant regimes
used is shown in online supplementary table S1.
Table 2 shows the timing of major bleeding, deﬁnition
of major bleeding used in the individual studies and the
incidence of major bleeding in each study. While many
of the studies did not report when assessment for major
bleeding took place (n=15), 15 of the studies clearly
stated that they evaluated in-hospital major bleeding.
The deﬁnitions of major bleeding also varied among the
included studies and formal deﬁnitions of major bleed-
ing included TIMI, GUSTO, STEEPLE, HORIZON-AMI,
CRUSADE, BARC and REPLACE-2 deﬁnitions. These
deﬁnitions are summarised in online supplementary
table S2. Follow-up of patients in the studies included in
this analysis varied from 48 h to more than 3 years. The
impact of major bleeding on clinical outcomes was
adjusted for baseline covariates in 22 studies (490 699
participants) while in 20 studies (42 634 participants)
only unadjusted outcomes were reported.
Quality assessment
Online supplementary table S3 shows the quality assess-
ment for included studies. Ascertainment of bleeding
and mortality varied from data collection from medical
record reviews to prospective evaluation in trials where
independent committees adjudicated bleeding and
outcome events.
Major bleeding and risk of mortality at any time point
The impact of major bleeding on mortality outcomes
was studied in 40 studies reporting outcomes in 525 691
patients. In total, 66 016 major bleeds were reported.
Crude rates or risk estimates for mortality in individual
studies are shown in online supplementary table S4.
Mortality rate was 3595/62 036 (5.8%, 28 studies) in
patients who sustained a major bleed and 8937/370 522
(2.4%, 28 studies) in patients not experiencing major
bleeding complications.
Meta-analysis of these data demonstrated that the
overall risk of mortality was signiﬁcantly greater among
patients who sustained major bleeding complications
periprocedurally (ﬁgure 1). The risk estimate for mortal-
ity was signiﬁcantly lower in the subgroup of studies,
which adjusted for potential confounders (OR 3.31
(2.86 to 3.82), I2=80%, 491 565 participants compared
to the OR calculated in those studies that did not adjust
for baseline covariates; OR 6.75 (4.99 to 9.12), I2=62%,
34 126 participants).
Major bleeding and risk of MACEs at any time point
The impact of major bleeding on MACEs outcomes was
studied in 13 studies reporting outcomes in 69 843
patients. Crude rates or risk estimates for MACEs in indi-
vidual studies are shown in tables 3 and 4; 757 major
bleeds (6.8%) were reported.
MACE rates were 295/1701 (17.3%) in patients who
sustained a major bleed and 2101/38 520 (5.4%) in
patients not experiencing major bleeding complications.
The overall risk of MACEs was signiﬁcantly higher
among patients with major bleeds (ﬁgure 2). The risk of
MACEs did not signiﬁcantly differ in the subgroup of
studies that adjusted for baseline covariates (OR 3.89
(3.26 to 4.64), I2=42%, 25 829 participants as compared
to those that did not adjust for baseline covariates OR
3.12 (2.32 to 4.19), I2=52%, 101 184 participants).
Mortality with major bleeding at different follow-up durations
The adjusted risk of mortality was signiﬁcantly greater
among patients with major bleeds at all time points eval-
uated (ﬁgure 3). For 30-day mortality, adjusted risk was
OR 3.24 (2.73 to 3.84, I2=81%, 11 studies, 403 457 parti-
cipants) and at 6 months, the OR remained elevated at
3.23 (2.92 to 3.57, I2=0%, 4 studies, 50 872 participants;
table 3). At the 1-year time point, the risk of mortality
was OR 3.64 (2.39 to 5.56, I2=89%, 9 studies).
MACEs with bleeding at different follow-up durations
Analysis of the impact of major bleeding on MACEs out-
comes at different time points was stratiﬁed into risk of
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Table 1 Study design, year of study, country of origin and participant inclusion criteria
Study ID Design Date of study
Number of
centres Country Inclusion criteria
Amlani et al 32 Prospective cohort May 2003 to July 2007 Single centre Canada Patients with STEMI
Ariza-Sole et al 33 Prospective cohort October 2009 to April
2012
Single centre Spain Patients with STEMI
Barthélémy et al 20 Prospective cohort NA Single centre France Patients in E-Paris Registry with STEMI and PCI
Bertrand et al 34 Post hoc analysis of
RCT
October 2003 to April
2005
Single centre Canada Patients in EASY trial with PCI without STEMI
Boden et al 35 Cohort NA NA The
Netherlands
Patients with STEMI and PCI
Budaj et al 36 Post hoc analysis of
RCT
NA Multicentre International Patients with NSTEMI ACS. Note that only 64–79% had PCI
Cayla et al 18 Post hoc analysis of
RCT
NA Multicentre France Patients in ABOARD trial with NSTEMI and PCI
Cayla et al 37 Post hoc analysis of
RCT
NA Multicentre International Patients in ATOLL study with STEMI and PCI
Chhatriwalla et al 14 Matched cohort 2004 to 2011 Multicentre USA Patients in the CathPCI Registry
Correia et al 38 Cohort August 2007 to
December 2010
Multicentre Brazil Patients with ACS. Note that only 76–90% had coronary
angiogram
Eikelboom et al 28 Post hoc analysis of
RCTs
NA Multicentre International Patients in OASIS 1 and 2 and CURE who had ACS. Note
that only 10–11% had PCI/stent/atherectomy
Fuchs et al 21 Prospective cohort January 2001 to June
2005
Single centre Israel Patients with STEMI and PCI
Gitt et al 39 Cohort October 2006 to
October 2008
Multicentre International Patients with ACS. Note that only 65–82% had primary/rescue
PCI
Giugliano et al 8 Post hoc analysis of
RCT
NA Multicentre International Patients in ExTRACT-TIMI 25 trial where patients received
fibrinolysis
Hermanides et al 22 Prospective cohort January 1991 to
December 2004
Single centre The
Netherlands
Patients with STEMI and PCI
Kaul et al 40 Post hoc analysis of
RCT
May 2004 to August
2008
Multicentre International Patients with NSTEMI
Kikkert et al 41 Prospective cohort January 2003 to July
2008
Single centre The
Netherlands
Patients with STEMI and PCI
Kinnaird et al 11 Retrospective cohort 1991 to 2000 NA USA Patients who underwent PCI
Le May et al 42 Cohort May 2005 to July 2010 NA Canada Patients with STEMI and PCI
Lee et al 43 Prospective cohort February 2003 to March
2006
NA Korea Patients with PCI with DES
Lemesle et al 27 Cohort January 2000 to
December 2007
Single centre USA Patients ≥80 years of age with PCI
Lindsey et al 44 Prospective cohort July 2004 to January
2006
Multicentre USA Patients in EVENT registry with PCI
Lopes et al 45 Retrospective cohort November 2001 to
December 2006
Multicentre USA Patients in CRUSADES registry and subset with PCI
Continued
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Table 1 Continued
Study ID Design Date of study
Number of
centres Country Inclusion criteria
Matic et al 46 Cohort August 2009 to
December 2012
NA Serbia Patients with STEMI and PCI
Matic et al 47 Cohort August 2009 to
December 2010
NA Serbia Patients with STEMI and PCI
Matic et al 48 Prospective cohort August 2009 to
December 2010
NA Serbia Patients with STEMI and PCI
Mehran et al 2 Post hoc analysis of
RCTs
NA Multicentre International Patients in REPLACE-2, ACUITY and HORIZONS-AMI trial
with PCI
Montalescot et al 25 Post hoc analysis of
RCT
December 2005 to
December 2006
Multicentre International Patients in STEEPLE trial who underwent elective PCI
Mrdovic et al 49 Cohort February 2006 to
December 2009
Single centre Serbia Patients with STEMI and PCI
Musumeci et al 50 Cohort June 2005 to June
2008
Multicentre Italy Patients with PCI and DES
Ndrepepa et al 17 Post hoc analysis of
RCT
September 2005 to
January 2008
NA Germany Patients in ISAR-REACT-3 trial with PCI
Ndrepepa et al 23 Post hoc analysis of
RCT
NA NA Germany Patients in ISAR-REACT, ISAR-SWEET, ISAR-SMART and
ISAR-REACT-2 trials with PCI
Pierre-Louis et al 51 Cohort NA NA USA Patients with ACS and PCI
Pilgrim and Wenaweser 52 Cohort May 2002 to December
2005
Single centre Switzerland Patients with PCI
Polanska-Skrzypczyk
et al 53
Prospective cohort February 2001 to
October 2002
Single centre Poland Patients with STEMI and PCI
Poludasu et al 54 Prospective cohort July 2001 to May 2010 Multicentre USA Patient with PCI
Rao et al 24 Post hoc analysis of
RCTs
NA Multicentre International Patients in GUSTO IIb, PURSUIT and PARAGON A/B. Note
that only 11–30% had PCI
Rossini et al 55 Cohort NA NA USA Patients with PCI and DES
Urban et al 56 Prospective cohort May 2006 to April 2008 Multicentre International Patients in e-SELECT registry with PCI and DES
Valente et al 19 Prospective cohort January 2004 to
December 2008
Single centre Italy Patients in Intensive Cardiac Care Florence STEMI Registry
who had STEMI and PCI
Yoon et al 57 Cohort NA NA Korea Patients in IRS DES registry with PCI and DES
Zheng et al 58 Retrospective cohort January 2004 to
January 2008
Single centre China Patients with elective or urgent PCI
ACS, acute coronary syndromes; DES, drug-eluting stent; NA, not applicable; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; RCT, randomised
controlled trial; STEMI, ST-elevation myocardial infarction.
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Table 2 Timing of bleeding, definition of major bleeding and follow-up
Study ID
Timing of
bleeding Major/severe bleeding criteria
Number of
participants in
bleeding group
Number of
participants in
control group Follow-up
Amlani et al 32 Within 30 days Haemoglobin drop ≥5 g/dL, intracranial haemorrhage,
bleeding requiring surgery or blood transfusion of at least
2 units
152 (67 had PCI) 1237 (566 had PCI) 30 days
Ariza-Sole et al 33 In-hospital CRUSADE 33 1031 Mean follow-up
344 days
Barthélémy et al 20 In-hospital TIMI, GUSTO, STEEPLE Total 671 NA 1 year
Bertrand et al 34 Unclear REPLACE-2 19 1329 30 days,
6 months,
1 year
Boden et al 35 In-hospital CRUSADE 203 762 1 year
Budaj et al 36 Up to 180 days ESSENCE 771 (30 days), 937
(180 days)
18 851 (30 days),
18 851(180 days)
180 days
Cayla et al 18 30 days STEEPLE 19 333 30 days
Cayla et al 37 30 days STEEPLE 42 868 30 days
Chhatriwalla et al 14 In-hospital CathPCI Registry definition 56 078 224 312 In-hospital
Correia et al 38 In-hospital BARC type 3 or 5 29 426 In-hospital
Eikelboom et al 28 Within 30 days Bleeding that was significantly disabling, bleeding requiring
transfusion of ≥2 units of packed cells or bleeding that was
life threatening
783 3363 30-day mortality
Fuchs et al 21 Unclear TIMI 27 804 30 days and
6 months
Gitt et al 39 In-hospital Drop in haemoglobin of >5 g/dL or haematocrit of >15% 281 8451 In-hospital
Giugliano et al 8 Up to day 8 TIMI 309 20 014 30 days
Hermanides et al 22 48 h TIMI 80 4371 30 days and
1 year
Kaul et al 40 Up to 120 h after
randomisation
GUSTO 598 8808 30 days
Kikkert et al 41 Unclear TIMI 35 331 1–30 days
Kinnaird et al 11 Unclear TIMI 588 8992 In-hospital
Le May et al 42 Unclear TIMI 91 1941 6 months
Lee et al 43 Median 1366 days STEEPLE 148 3022 Median
1366 days
Lemesle et al 27 In-hospital Decrease in haematocrit of ≥15% and/or the occurrence of
a major haematoma/gastrointestinal bleeding/intracerebral
bleeding
127 2639 6 months
Lindsey et al 44 In-hospital TIMI 180 5781 1 year
Lopes et al 45 In-hospital CRUSADE 3902 28 993 30 days, 1 year,
3 year, >3 years
Matic et al 46 Unclear GUSTO 32 738 In-hospital
Matic et al 47 Unclear HORIZONS-AMI 88 1154 30 day
Continued
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Table 2 Continued
Study ID
Timing of
bleeding Major/severe bleeding criteria
Number of
participants in
bleeding group
Number of
participants in
control group Follow-up
Matic et al 48 Unclear BARC 114 1558 1 year
Mehran et al 2 30 days TIMI 267 17 034 Up to 1 year
Montalescot et al 25 48 h STEEPLE 3528 (total) NA 1 year
Mrdovic et al 49 Unclear TIMI 22 2074 30 days and
1 year
Musumeci et al 50 30 days,
12 months, any
follow-up
TIMI 52 1385 3 years
Ndrepepa et al 17 Unclear REPLACE-2 555 4015 1 year
Ndrepepa et al 23 In-hospital TIMI, REPLACE-2, BARC Total 12 459 NA 30 days, 1 year
Pierre-Louis et al 51 In-hospital Intracerebral or intraocular bleeding, clinical bleeding
requiring blood transfusion, clinical bleeding with a
reduction in haematocrit >10 points, retroperitoneal or
gastrointestinal bleeding, access site bleeding requiring
intervention, and ≥4 cm diameter vascular access site
haematoma
34 600 In-hospital
Pilgrim and
Wenaweser52
In-hospital TIMI 48 3787 30 days
Polanska-Skrzypczyk
et al 53
In-hospital TIMI 40 1024 1 year
Poludasu et al 54 Unclear HORIZONS-AMI 396 11 595 2.3 years
Rao et al 24 Unclear GUSTO 2908 23 544 Up to 6 months
Rossini et al 55 Unclear TIMI 57 1301 1 year
Urban et al 56 Unclear STEEPLE Total 15 147 NA 360 days
Valente et al 19 In-hospital TIMI, ACUITY Total 991 NA In-ICCU
Yoon et al 57 In-hospital BARC type 2–5 234 5932 2 years
Zheng et al 58 Unclear TIMI 27 385 1 year
ICCU, intensive coronary care unit; NA, not applicable; PCI, percutaneous coronary intervention.
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MACE <1 year and ≥1 year due to the limited number of
studies presenting MACE data and its relationship with
time. The adjusted risk of MACE <1 year was OR 3.96
(3.26 to 4.81, I2=53%, 2 studies, 47 422 participants) and
for ≥1 year was OR 3.19 (1.89 to 5.37, 1 study, 3170 par-
ticipants; table 3).
Adverse outcomes and different definitions
for major bleeding
The impact of different deﬁnitions of major bleeding on
mortality and MACEs outcomes are presented in table 4.
REPLACE-2 (OR 6.69 (2.26 to 19.81), I2=84%, 3 studies,
17 996 participants) deﬁnition of major bleeding had
Figure 1 Adjusted risk of mortality with and without major bleed after percutaneous coronary intervention.
Table 3 Summary of risk of mortality and MACEs among patients with and without major bleed after percutaneous coronary
intervention at different time points
Duration OR I2 (%)
Number of
participants
Number of events
in bleed group/total
Number of events in
non-bleed group/total
Adjusted risk of mortality
30 days8 14 24 28 32 36 38 39 40 41 45 3.24 (2.73 to 3.84) 81 403 457 3307/59 630 7645/317 375
6 months24 27 36 42 3.23 (2.92 to 3.57) 0 50 872 154/1028 1119/20 606
1 year2 22 23 25 44 48 53 56 3.64 (2.39 to 5.56) 89 74 637 160/2494 677/36 167
Adjusted risk of MACEs
<1 year24 34 36 3.96 (3.26 to 4.81) 53 47 422 175/790 1204/20 180
>1 year43 3.19 (1.89 to 5.38) NA 3170 NA NA
MACEs, major adverse cardiovascular events; NA, not applicable.
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the greatest impact on mortality outcomes, while the
ACUITY/HORIZONS-AMI had the least impact (OR
1.51 (1.11 to 2.05), I2=12%, 1 study, 13 233 participants).
Sensitivity analysis
Sensitivity analysis excluding studies where not all partici-
pants had PCI did not signiﬁcantly alter the pooled ana-
lysis for association between major bleeding and mortality
(OR 3.16 (2.61 to 3.81), I2=75%, 372 449 participants).
DISCUSSION
Advances in antithrombotic and antiplatelet therapy
have improved outcomes following PCI through the
reduction of ischaemic events although this has been at
the expense of increased procedure-related bleeding
complications. Our meta-analysis of 42 studies including
over half a million patients conﬁrms that major bleeding
is independently associated with a threefold increase in
mortality and MACEs outcomes, and that this increased
mortality and MACEs risk observed following a major
bleed is sustained for periods of over 1 year. We also
show that major bleeding events as deﬁned by different
contemporary bleeding deﬁnitions have differential
impacts on mortality outcomes, with 1.5–6.7-fold
increases in mortality observed depending on the deﬁn-
ition of major bleeding used.
There are a number of potential mechanisms that may
underlie the relationship between major bleeding and
adverse mortality outcomes. Patients that sustain major
bleeding complications post PCI are more likely to be
older, have renal failure, undergo PCI for STEMI/
NSTEMI presentations, present with haemodynamic
compromise or have a history of heart failure2 59 that also
Table 4 Summary of risk of mortality and MACEs among patients with and without major bleed after percutaneous coronary
intervention with different definitions of bleeding
Mortality MACEs
Definition of major bleed OR I2 (%)
Number of
participants Definition OR I2
Number of
participants
BARC23 38 48 5.40 (1.74 to 16.74) 88 14 550 BARC NA NA NA
CRUSADE33 35 45 3.69 (1.68 to 8.12) 85 14 055 CRUSADE NA NA NA
GUSTO24 40 46 4.30 (3.76 to 4.92) 0 27 222 GUSTO24 4.37 (3.78 to 5.07) NA 26 452
HORIZON-AMI47 54 1.51 (1.11 to 2.05) 12 13 233 HORIZON-AMI NA NA NA
REPLACE17 23 34 6.69 (2.26 to 19.81) 84 17 996 REPLACE NA NA NA
STEEPLE18 25 37 43 56 6.59 (3.89 to 11.16) 53 23 107 STEEPLE43 3.19 (1.89 to 5.37) NA 3170
TIMI2 8 11 19 20 21 22 42
44 49 50 52 53 55
5.15 (4.01 to 6.61) 69 69 449 TIMI21 2.41 (1.42 to 4.35) NA 1348
Other14 27 28 32 36 39 51 3.34 (2.59 to 4.32) 76 346 670 Other36 3.99 (3.3 to 4.82) NA 19 622
MACEs, major adverse cardiovascular events; NA, not applicable.
Figure 2 Adjusted risk of major adverse cardiovascular event with and without major bleed after percutaneous coronary
intervention.
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independently predict adverse mortality outcomes them-
selves. Many previous studies17–21 that have reported on
the prognostic impact of major bleeds have not
accounted for differences in such baseline covariates that
are themselves known to impact on mortality outcomes,
which would overestimate the mortality risks associated
with a major bleed. For example, in an analysis from the
Global Registry of Acute Coronary Events (GRACE),
major bleeding was no longer associated with 6-month
mortality after adjustment for the known comorbidities
with the authors concluding that comorbidities asso-
ciated with major bleeding accounting for the higher
rate of mortality in patients who bled.15 Consistent with
this, we have observed that in meta-analysis of studies that
do not adjust for baseline covariates, major bleeding is
associated with a sixfold increased risk in mortality, but
this decreases to a threefold independent increase in
mortality once baseline covariates are adjusted for, sug-
gesting that major bleeding is independently linked to
mortality and MACEs outcomes.
The potential mechanisms by which a major bleed
adversely impacts on clinical outcomes are numerous.
Major bleeds such as an intracranial haemorrhage or
severe blood loss as can occur in a gastrointestinal haem-
orrhage may result in mortality directly, although such
bleeding events would not explain the persistent mortal-
ity risk observed for over a year following a major bleed-
ing event in our meta-analysis. Major bleeds may
necessitate the discontinuation of antiplatelet or antith-
rombotic medications that increase the risk for stent
thrombosis, a strong independent predictor of mortality
outcomes in the short and longer term (>1 year).60
Furthermore, increased production of erythropoietin in
response to anaemia that occurs following a major bleed
may contribute to a prothrombotic systemic state beyond
the acute phase through platelet activation and induc-
tion of plasminogen activator inhibitor-1 (PAI-1).61 62
Treatment with erythropoietin has been associated with
increased risk of thrombosis in critical care patients63
and increase in the composite endpoint of death, acute
myocardial infarction, stroke and stent thrombosis in
patients with STEMI.64 Blood transfusions have been
linked to adverse shorter and longer term mortality65
and have been shown to predict 30-day mortality66 inde-
pendently of bleeding and haematocrit. Adverse mortal-
ity outcomes associated with blood transfusions occur
through a number of mechanisms including prothrom-
botic effects mediated through acute platelet release of
CD40 ligand,67 platelet activation and induction of
PAI-161 an inhibitor of endogenous ﬁbrinolytic mechan-
isms. These increased risks of mortality also extend to
non-red blood cell transfusions such as platelets or
plasma/cryoprecipitate that may also be utilised follow-
ing a periprocedural major bleed.68
Our observations of a differential impact of different
major bleeding deﬁnitions on mortality outcomes is par-
ticularly pertinent suggesting that the choice of bleeding
deﬁnition used has signiﬁcantly inﬂuenced the outcome
of previous studies, since the deﬁnition employed will
inﬂuence the prevalence of reported bleeds as well as
their prognostic impact. For example, in the RIVAL
study69 non-CABG related major bleeding as deﬁned by
the study was not signiﬁcantly different between the
radial and femoral arms of the study (OR=0.73, 95% CI
0.43 to 1.23; p=0.9), while use of the ACUITY major
bleeding criterion was associated with a statistically sig-
niﬁcant reduction in major bleeding in the radial arm
of the study (OR=0.43, 95% CI 0.32 to 0.57; p<00001).
Similarly, in the SYNERGY trial that used the GUSTO
and TIMI major deﬁnition of bleeding, the enoxaparin
arm was associated with a signiﬁcantly higher rate of
major bleeding as deﬁned by TIMI major criteria but no
difference in major bleeding as deﬁned by the GUSTO
major deﬁnition. Deﬁnitions that encompass less severe
bleeding events (such as the ACUITY deﬁnition) are not
as strongly linked to adverse events and therefore may
not be a powerful means of evaluating bleeding avoid-
ance strategies. In order to prove efﬁcacy for bleeding
avoidance the use of a more discriminative deﬁnition
would be preferable.
Our meta-analysis has a number of potential limita-
tions. First, an inherent limitation of any meta-analysis is
that of publication bias; studies that show a neutral
outcome in mortality are less likely to be published than
those that show a positive outcome and thus tend to bias
any meta-analysis of published data towards a more posi-
tive outcome. Second, studies included in this
meta-analysis often used different antithrombotic and
antiplatelet regimes for the PCI procedures undertaken
for different indications, hence it is unclear whether the
prognostic impact of a major bleed differs with different
antiplatelet/anticoagulant combinations or whether it
differs in the elective/acute coronary syndrome setting.
Finally, our current analysis does not provide insight into
whether the timing of the major bleed in relation to the
index PCI procedure has a differential impact on mor-
tality outcomes.
In conclusion, our meta-analysis of 42 studies includ-
ing over half a million patients has revealed that major
bleeding is independently associated with a threefold
Figure 3 Risk of mortality with major bleed with different
duration of follow-up.
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increase in mortality and MACEs outcomes, and that
this increased mortality and MACEs risk observed follow-
ing a major bleed is observed for periods of over 1 year.
We also show that major bleeding events as deﬁned by
different contemporary bleeding deﬁnitions have differ-
ential impacts on mortality outcomes. Given the signiﬁ-
cant impact of major bleeding on mortality outcomes,
formal bleeding risk assessment should be undertaken
as part of the decision-making process for PCI proce-
dures and bleeding avoidance strategies such as optimal
pharmacotherapy and access site choice should be
actively undertaken, particularly in those patients at
highest baseline risk for bleeding complications.
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